Uniunea Europeană - română - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - alte preparate dermatologice - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

meda pharma gmbh & co. kg - crema - 1%

Uniunea Europeană - română - EMA (European Medicines Agency)

zoetis belgium sa - oclacitinib maleat - agenți pentru dermatită, cu excepția corticosteroizilor - câini - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.

Uniunea Europeană - română - EMA (European Medicines Agency)

zoetis belgium sa - lokivetmab - alte preparate dermatologice, agenți pentru dermatita, cu excepția corticosteroizi - câini - tratamentul manifestărilor clinice ale dermatitei atopice la câini.

Uniunea Europeană - română - EMA (European Medicines Agency)

leo pharma a/s - tacrolimus - dermatita, atopică - alte preparate dermatologice - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. loc de patru sau de mai multe ori pe an), care au avut un răspuns inițial la un maxim de șase săptămâni de tratament de două ori pe zi tacrolimus unguent (leziuni eliminate, aproape șterse sau ușor afectate).

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

novartis pharma gmbh - germania - pimecrolimus - crema - 10mg/g - alte preparate de uz dermatologic alte preparate de uz dermatologic

Uniunea Europeană - română - EMA (European Medicines Agency)

pfizer europe ma eeig  - crisaborole - dermatita, atopică - alte preparate dermatologice - staquis este indicat pentru tratamentul formelor ușoare și moderate de dermatita atopica la adulți, adolescenți și copii cu vârsta de 2 ani cu ≤ 40% suprafața corporală (bsa) afectate.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

meda manufacturing - franta - pimecrolimus - crema - 10mg/g - alte preparate de uz dermatologic alte preparate de uz dermatologic

Uniunea Europeană - română - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatita, atopică - alte preparate dermatologice - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

Uniunea Europeană - română - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenți pentru dermatită, cu excepția corticosteroizilor - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.